| Drug General Information |
| Drug ID |
D05AMX
|
| Former ID |
DNC002675
|
| Drug Name |
Cysteinesulfonic Acid
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C3H7NO5S
|
| Canonical SMILES |
C(C(C(=O)O)N)S(=O)(=O)O
|
| InChI |
1S/C3H7NO5S/c4-2(3(5)6)1-10(7,8)9/h2H,1,4H2,(H,5,6)(H,7,8,9)
|
| InChIKey |
XVOYSCVBGLVSOL-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
137935, 4865768, 8168664, 14843148, 22389417, 29292597, 49747210, 51073780, 57310047, 76467629, 81051656, 85247149, 87359762, 103768181, 104295257, 119509107, 124409250, 125347436, 125536849, 125537019, 125793420, 126524646, 126546142, 127319592, 127319593, 129747382, 131309571, 134223550, 134990989, 135610185, 136351573, 137007738, 142872473, 162063452, 162293093, 163142782, 164054794, 164829183, 165252212, 179294070, 184535365, 186008906, 223359922, 226428332, 249927023, 252348681
|
| Target and Pathway |
| Target(s) |
M-phase inducer phosphatase 2 |
Target Info |
Inhibitor |
[1]
|
|---|
| mRNA of Protein tyrosine phosphatase-1B |
Target Info |
Inhibitor |
[1]
|
| Cathepsin L |
Target Info |
Inhibitor |
[1]
|
| Peptide deformylase |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Cell cycle
|
|
Progesterone-mediated oocyte maturation
|
|
MicroRNAs in cancerhsa04520:Adherens junction
|
|
Insulin signaling pathwayhsa04142:Lysosome
|
|
Phagosome
|
|
Antigen processing and presentation
|
|
Proteoglycans in cancer
|
|
Rheumatoid arthritis
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Wnt Signaling PathwayNetPath_25:FSH Signaling PathwayNetPath_16:IL4 Signaling Pathway
|
|
PANTHER Pathway
|
Cadherin signaling pathway
|
|
Pathway Interaction Database
|
PLK1 signaling events
|
|
FOXM1 transcription factor network
|
|
p38 signaling mediated by MAPKAP kinases
|
|
Aurora A signalinginsulin_pathway:Insulin Pathway
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
Signaling events mediated by PTP1B
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Signaling events mediated by TCPTP
|
|
IGF1 pathway
|
|
EGF receptor (ErbB1) signaling pathway
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
PDGFR-beta signaling pathway
|
|
N-cadherin signaling events
|
|
Reactome
|
Cyclin B2 mediated events
|
|
Cyclin A/B1 associated events during G2/M transition
|
|
Cyclin A:Cdk2-associated events at S phase entryR-HSA-354192:Integrin alphaIIb beta3 signaling
|
|
Regulation of IFNG signaling
|
|
Regulation of IFNA signaling
|
|
Growth hormone receptor signalingR-HSA-1236977:Endosomal/Vacuolar pathway
|
|
Collagen degradation
|
|
Degradation of the extracellular matrix
|
|
Trafficking and processing of endosomal TLR
|
|
Assembly of collagen fibrils and other multimeric structures
|
|
MHC class II antigen presentation
|
|
WikiPathways
|
Senescence and Autophagy in Cancer
|
|
MAPK Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Mitotic G2-G2/M phases
|
|
Cell CycleWP481:Insulin Signaling
|
|
Growth hormone receptor signaling
|
|
Leptin signaling pathway
|
|
Interferon gamma signaling
|
|
Interferon alpha/beta signaling
|
|
Integrin alphaIIb beta3 signalingWP2572:Primary Focal Segmental Glomerulosclerosis FSGS
|
| References |
| REF 1 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. |
|---|
